| CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma. | CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
Yamaguchi J, Ohka F, Lushun C, Motomura K, Aoki K, Takeuchi K, Nagata Y, Ito S, Mizutani N, Ohno M, Suzaki N, Takasu S, Seki Y, Kano T, Wakabayashi K, Oyama H, Kurahashi S, Tanahashi K, Hirano M, Shimizu H, Kitano Y, Maeda S, Yamazaki S, Wakabayashi T, Kondo Y, Natsume A, Saito R., Free PMC Article | 04/5/2023 |
| Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma. | Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.
Kirkegaard MK, Minderman M, Sjö LD, Pals ST, Eriksen PRG, Heegaard S. | 03/28/2023 |
| Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. | Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH., Free PMC Article | 12/3/2022 |
| The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review. | The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.
Xu PP, Shen R, Shi ZY, Cheng S, Wang L, Liu Y, Zhang L, Huang R, Ma X, Wu X, Yao H, Yu Y, Zhao WL. | 12/3/2022 |
| A New Missense Mutation in CD79B Leads to Autosomal Recessive Agammaglobulinemia in Two Siblings. | A New Missense Mutation in CD79B Leads to Autosomal Recessive Agammaglobulinemia in Two Siblings.
Genebrier S, Fusaro M, Lambert N, Roullaud S, Millot F, Picard C. | 02/5/2022 |
| Genetically, primary adrenal diffuse large B-cell lymphoma harbor a high prevalence of MYD88 L265P (24%) and CD79B mutations (52%) which may be involved in lymphomagenesis. | Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z, Zou Y, Liu W, Guan P, Tao Q, Xiang C, Zhang W, Ye Y, Yan J, Zhao S. | 08/1/2020 |
| primary vitreoretinal lymphoma had unique genetic features: an expression pattern different from activated B-cell type and relatively close to germinal center B-cell-type diffuse large B-cell lymphoma. CD79B mutations showed potential to serve as prognostic markers for CNS progression | Gene expression profiling of primary vitreoretinal lymphoma.
Arai A, Takase H, Yoshimori M, Yamamoto K, Mochizuki M, Miura O., Free PMC Article | 04/25/2020 |
| MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma. | MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V, Das A, Bal A, Srinivasan R, Das R, Prakash G, Malhotra P, Varma S. | 04/18/2020 |
| CD79B Y196 mutation occurs in 26% of patients with intravascular large B-cell lymphoma (IVLBCL) in Dutch study. | High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP. | 07/13/2019 |
| Detecting CD79B(Y196) in vitreous DNA may contribute to the confirmation of the diagnosis and may have a prognostic potential for patients with PVRL. | CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.
Yonese I, Takase H, Yoshimori M, Onozawa E, Tsuzura A, Miki T, Mochizuki M, Miura O, Arai A. | 04/27/2019 |
| mutational frequencies in CD79B and MYD88 greatly varied with respect to tissue distribution | Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M, Dreyling M, Lenz G, Gaumann A. | 01/12/2019 |
| CD79B mutations were found in six of 19 cases (31.6%) of primary CNS diffuse large B-cell lymphoma , all in the Y196 mutation hotspot | Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
Zheng M, Perry AM, Bierman P, Loberiza F Jr, Nasr MR, Szwajcer D, Del Bigio MR, Smith LM, Zhang W, Greiner TC. | 08/4/2018 |
| Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of CD79B mutations. | Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB. | 10/28/2017 |
| hotspot mutations of CD79B Y196 and MYD88 L265 may serve as a genetic hallmark for primary central nervous system lymphoma | Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K. | 01/14/2017 |
| CD79B overexpression leading to activation of AKT/MAPK is a potential mechanism underlying primary ibrutinib resistance in ABC-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib. | CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
Kim JH, Kim WS, Ryu K, Kim SJ, Park C. | 01/14/2017 |
| Novel CD79B variations in mature B-cell non-Hodgkin's lymphoma patients were detected. | Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed.
Cetin GO, Baris IC, Caner V, Sarikepe B, Sen Turk N, Tepeli E, Hacioglu S, Sari I, Bagci G, Keskin A. | 12/17/2016 |
| MYD88 L265P and CD79B mutations were frequently detected in primary breast diffuse large B-cell lymphoma. | Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K, Takata K, Chuang SS, Miyata-Takata T, Sato Y, Satou A, Hashimoto Y, Tamura M, Nagakita K, Ohnishi N, Noujima-Harada M, Tabata T, Kikuti YY, Maeda Y, Nakamura N, Tanimoto M, Yoshino T. | 07/2/2016 |
| Oncogenic CD79B mutation is associated with primary diffuse large B-cell lymphomas of central nervous system. | Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S, Ishida Y, Matsuno A, Yamazaki K. | 05/7/2016 |
| Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. | Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
Kersten MJ, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST., Free PMC Article | 09/26/2015 |
| Abberant expression of CD79b in non-B cells caused unwanted reactivity, rendering CD79b unsuitable for T-cell receptor - based immunotherapies. | Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.
Jahn L, Hombrink P, Hassan C, Kester MG, van der Steen DM, Hagedoorn RS, Falkenburg JH, van Veelen PA, Heemskerk MH. | 04/25/2015 |
| Phosphorylation of CD79a causes a decrease in helical propensity in the C-terminal region, for CD79b, the opposite was observed and phosphorylation resulted in an increase of helical propensity in the C-terminal part. | Tyrosine phosphorylation within the intrinsically disordered cytosolic domains of the B-cell receptor: an NMR-based structural analysis.
Rosenlöw J, Isaksson L, Mayzel M, Lengqvist J, Orekhov VY., Free PMC Article | 01/24/2015 |
| results suggest that MYD88 mutations, and to a lesser extent CD79B mutations, are important drivers of lymphomagenesis in PTL | High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ, Spaargaren M, Pals ST. | 05/3/2014 |
| CD79B and MYD88 mutations are associated with an older age at onset in diffuse large b-cell lymphoma with a significant overlap, which did not affect the outcome of the disease. | CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, Ko YH. | 05/3/2014 |
| CD79B point mutation is associated with B-cell non-Hodgkin lymphomas. | EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.
Saieg MA, Geddie WR, Boerner SL, Bailey D, Crump M, da Cunha Santos G., Free PMC Article | 10/19/2013 |
| Data indicate a secondary promoter located within exon 2 maintained full levels and specificity of hCD79b transcription. | Identification of a secondary promoter within the human B cell receptor component gene hCD79b.
Yoo EJ, Cooke NE, Liebhaber SA., Free PMC Article | 09/7/2013 |